ProfileGDS5678 / 1452534_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 96% 97% 95% 95% 96% 96% 96% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.9851596
GSM967853U87-EV human glioblastoma xenograft - Control 29.129696
GSM967854U87-EV human glioblastoma xenograft - Control 39.0244396
GSM967855U87-EV human glioblastoma xenograft - Control 49.2276696
GSM967856U87-EV human glioblastoma xenograft - Control 59.0233396
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.0619797
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2714895
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.4862495
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.8426296
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.0799896
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.8491396
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.2438797
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.1665297
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.2002397